CD274 and neoplasm: The combination of entinostat and NHS-IL-12 was demonstrated to induce robust suppression of tumors with a range of immunogenicity and sensitivity to PD-L1 blockade, including EMT6 (breast), CT26 (Kras G12D) and MC38 (colon), also inducing tumor-specific protective memory (52).